Abstract
In the treatment of early breast cancer, the addition of a sequential taxane following an anthracycline-based regimen has improved patient outcomes (1), with studies suggesting that weekly solvent-based paclitaxel given after an anthracycline regimen significantly reduces the risk of relapse (2,3).
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have